Isocarboxazid: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: January 9, 2026🚩 Report this page

Isocarboxazid

Monoamine Oxidase Inhibitors, Non-Selective

GB MHRA

Drug class: Monoamine Oxidase Inhibitors, Non-Selective
Availability: See label
Markets covered: 1
Products on record: 1

N06AFMonoamine Oxidase Inhibitors, Non-Selective

Overview

Isocarboxazid is an active pharmaceutical ingredient in the Monoamine Oxidase Inhibitors, Non-Selective group (N06AF). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	1	January 9, 2026

GBUnited Kingdom· MHRA

1 product

Uses

GBOfficial regulatory label· revised January 9, 2026[1]

For the treatment of the symptoms of depressive illness.

How to take

GBOfficial regulatory label

Drug interactions

Known interactions involving Isocarboxazid. Select one for details. This list is informational and not a complete interaction checker.

Alfentanil Almotriptan Amitriptyline Amoxapine Amphetamine Apraclonidine Atomoxetine Benzhydrocodone Benzphetamine Buprenorphine Bupropion Buspirone Butorphanol Carbamazepine Citalopram Clomipramine Cocaine Codeine Cyclobenzaprine Desflurane Desipramine Desvenlafaxine Deutetrabenazine Dexfenfluramine Dexmethylphenidate Dextroamphetamine Dextromethorphan Dezocine Diethylpropion Dihydrocodeine Dihydroergotamine Dolasetron Dopamine Doxapram Doxepin Doxylamine Droperidol Duloxetine Eletriptan Enflurane Entacapone Ephedrine Ergotamine Escitalopram Esketamine Etomidate Fenfluramine Fentanyl Fluoxetine Fluvoxamine Fospropofol Frovatriptan Granisetron Halothane Hydrocodone Hydromorphone Imipramine Iohexol Iopamidol Isoflurane Isometheptene Ketamine Lasmiditan Levodopa Levomilnacipran Levorphanol Linezolid Lisdexamfetamine Lorcaserin Maprotiline Mazindol Meperidine Mephentermine Metaraminol Methadone Methohexital Methoxyflurane Methyldopa Methylene Blue Methylphenidate Milnacipran Mirtazapine Morphine Nalbuphine Naratriptan Nefazodone Nitrous Oxide Nortriptyline Oliceridine Ondansetron Opicapone Opium Oxcarbazepine Oxycodone Oxymorphone Ozanimod Palonosetron Paroxetine Pentazocine Phendimetrazine Phenelzine Phentermine Phenylephrine Phenylpropanolamine Procarbazine Propofol Propoxyphene Protriptyline Pseudoephedrine Rasagiline Remifentanil Rizatriptan Safinamide Selegiline Sertraline Sevoflurane Sibutramine Solriamfetol Sufentanil Sumatriptan Tapentadol Tetrabenazine Thiopental Tolcapone Tramadol Tranylcypromine Trazodone Trimipramine Tryptophan Valbenazine Venlafaxine Vilazodone Vortioxetine Zolmitriptan Acebutolol Acetohexamide Acrivastine Albuterol Aldesleukin Alfuzosin Aliskiren Alprazolam Altretamine Amifampridine Amiloride Amlodipine Amobarbital Amyl Nitrite Apomorphine Arformoterol Aripiprazole Asenapine Atenolol Avanafil Azatadine Azelastine Azilsartan Baclofen Benazepril Bendroflumethiazide Benzthiazide Bepridil Betaxolol Bisoprolol Brexanolone Brexpiprazole Brimonidine Brivaracetam Bromocriptine Brompheniramine Bumetanide Butabarbital Butalbital Cannabidiol Captopril Carbinoxamine Cariprazine Carisoprodol Carteolol Carvedilol Cenobamate Cetirizine Chlorcyclizine Chlordiazepoxide Chlormezanone Chlorothiazide Chlorphenesin Chlorpheniramine Chlorpromazine Chlorpropamide Chlorthalidone Chlorzoxazone Clemastine Clevidipine Clobazam Clonazepam Clonidine Clorazepate Clozapine Cyclandelate Cyclizine Cyproheptadine Dantrolene Deserpidine Dexbrompheniramine Dexmedetomidine Diazepam Diazoxide Diltiazem Diphenhydramine Dipivefrin Disulfiram Dobutamine Doxazosin Dronabinol Droxidopa Enalapril Epinephrine Eplerenone Epoprostenol Eprosartan Eslicarbazepine Esmolol Estazolam Eszopiclone Ethacrynate Ethanol Ethosuximide Ethotoin Ezogabine Felbamate Felodipine Fenoldopam Flavoxate Flibanserin Fluphenazine Flurazepam Formoterol Fosinopril Fosphenytoin

Showing 240 of 449. Type above to find a specific drug.

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]MHRA (UK) · PL168530108 · revised January 9, 2026

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised January 9, 2026[1]

In general, Isocarboxazid is well tolerated by the majority of patients. Side-effects, if they occur, are those common to the group of monoamine oxidase inhibitors. The most frequently reported have been orthostatic hypotension, associated in some patients with disturbances in cardiac rhythm, peripheral oedema, complaints of dizziness, dryness of the mouth, nausea and vomiting, constipation, blurred vision, insomnia, drowsiness, weakness and fatigue.
These side-effects can usually be controlled by dosage reduction. There have been infrequent reports of mild headaches, sweating, paraesthesiae, peripheral neuritis, hyperreflexia, agitation, overactivity, muscle tremor, confusion and other behavioural changes, difficulty in micturition, impairment of erection and ejaculation, and skin rashes.
Although rare, blood dyscrasias (purpura, granulocytopenia) have been reported. Response to Isocarboxazid may be accompanied by increased appetite and weight gain. 4). Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card Scheme in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised January 9, 2026[1]

Some monoamine oxidase inhibitors have occasionally caused hepatic complications and jaundice in patients, therefore regular monitoring of liver function should be carried out during Isocarboxazid therapy. If there is any evidence of a hepatotoxic reaction, the drug should be withdrawn immediately.
The drug should be used cautiously in patients with impaired renal function, to prevent accumulation taking place, and also in the elderly or debilitated and those with cardiovascular disease, diabetes or blood dyscrasias. In restless or agitated patients, Isocarboxazid may precipitate states of excessive excitement.
Isocarboxazid appears to have varying effects in epileptic patients; while some have a decrease in frequency of seizures, others have more seizures. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Suicide/suicidal thoughts or clinical worsening Depression is associated with an increased risk of suicidal thoughts, self harm and suicide (suicide-related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs.
It is general clinical experience that the risk of suicide may increase in the early stages of recovery. Patients with a history of suicide-related events, or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment.
A meta-analysis of placebo-controlled clinical trials of antidepressant drugs in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old.
Close supervision of patients and in particular those at high risk should accompany drug therapy especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drug interactions

Drugs in the same class

Sources & citations